Table 2.
Quantitative cohort: Country of residence, marital status, and cancer history
| Total (N = 103) |
RRBSO (n = 17) |
RRBSO + ETBSOc (n = 26) |
SM (n = 22) |
AMC (n = 38) |
||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | |
| Country of residence | ||||||||
| Canada | 16 | 94.12 | 25 | 96.15 | 20 | 90.91 | 30 | 78.95 |
| Othera | 1b | 5.88 | 1 | 3.85 | 2 | 9.09 | 8 | 21.05 |
| Marital status | ||||||||
| Never married | 1 | 5.88 | 0 | 0 | 3 | 13.64 | 6 | 15.79 |
| Separated | 0 | 0 | 2 | 7.69 | 3 | 13.64 | 2 | 5.26 |
| Common law | 3 | 17.65 | 2 | 7.69 | 2 | 9.09 | 3 | 7.89 |
| Divorced | 0 | 0 | 1 | 3.85 | 1 | 4.55 | 1 | 2.63 |
| Married | 13 | 76.47 | 21 | 80.77 | 11 | 50.00 | 26 | 68.42 |
| Widowed | 0 | 0 | 0 | 0 | 2 | 9.09 | 0 | 0 |
| Cancer history | ||||||||
| BC Diagnosis | 5 | 29.41 | 2 | 7.69 | 0 | 0 | 0 | 0 |
| BC Treatment: Surgery | 2 | 11.76 | 1 | 3.85 | 0 | 0 | 0 | 0 |
| BC Treatment: Surgery and chemotherapy | 1 | 5.88 | 1 | 3.85 | 0 | 0 | 0 | 0 |
| BC Treatment: Surgery, chemotherapy, and radiation | 2 | 11.76 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other cancer diagnosis | 2 | 11.76 | 1 | 3.85 | 2 | 9.09 | 2 | 5.26 |
| Other cancer treatment: Surgery | 2 | 11.76 | 1 | 3.85 | 1 | 4.55 | 2 | 5.26 |
| Other cancer treatment: Surgery and radiation | 0 | 0 | 0 | 0 | 1 | 4.55 | 0 | 0 |
RRBSO, risk-reducing bilateral salpingo-oophorectomy; RRBSO + ETBSO, women with RRBSO taking estradiol therapy (ETBSO); SM, spontaneous menopause; AMC, age-matched controls; BC, breast cancer
aWestern, English-speaking country of residence outside of Canada
bParticipant did not report their country of residence
cTaking concurrent androgel (n = 2) and tibolone (n = 1)